A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

Bimekizumab showed higher PASI100 response rates at weeks 4 and 16 compared to brodalumab, indicating superior efficacy. Discontinuation due to inefficacy was more frequent with brodalumab, though ...

A second study, also published today in the same journal, looked at patients seen at the Beth Israel Deaconess Medical Center in Boston and found a lower uptake of maternal RSV vaccine and nirsevimab ...

vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study. 1 Conducted at a single academic center ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., particularly those 60 and older. Before respiratory syncytial virus (RSV) ...

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...